Ho Yeong Lim

Ho Yeong Lim is a leading HCC oncologist in South Korea contributing to Asian-specific clinical trials and regulatory approvals of systemic agents for hepatocellular carcinoma. He led the Korean phase 3 trial of rivoceranib (apatinib) in second-line HCC and has contributed to Asian sub-analyses of global HCC trials. His research addresses the unique epidemiology of hepatitis B-related HCC in Korea, responses to antiviral therapy in combination with systemic treatment, and Korean national HCC treatment guidelines. He participates in Asia-Pacific HCC research networks.